222110 — Pangen Biotech Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual cashflow statement for Pangen Biotech, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-4,356	-3,310	-4,494	-4,489	944
Depreciation
Amortisation
Non-Cash Items	1,219	811	624	1,092	744
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	-3,103	-2,349	-1,228	-1,642	-162
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-4,681	-3,324	-3,503	-3,451	2,987
Capital Expenditures	-772	-1,474	-734	-485	-374
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	9,190	-4,552	14,963	-86.1	-9,963
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	8,417	-6,026	14,229	-571	-10,337
Financing Cash Flow Items	77.3	62.7	59.7	-23.8	-9.43
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	77.3	10,112	-18,736	3,175	8,735
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	3,776	762	-8,009	-847	1,385